Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook

Int J Parasitol Drugs Drug Resist. 2021 Aug:16:102-118. doi: 10.1016/j.ijpddr.2021.05.007. Epub 2021 May 26.

Abstract

Emergence and spread of resistance in Plasmodium falciparum to the frontline treatment artemisinin-based combination therapies (ACTs) in the epicenter of multidrug resistance of Southeast Asia threaten global malaria control and elimination. Artemisinin (ART) resistance (or tolerance) is defined clinically as delayed parasite clearance after treatment with an ART drug. The resistance phenotype is restricted to the early ring stage and can be measured in vitro using a ring-stage survival assay. ART resistance is associated with mutations in the propeller domain of the Kelch family protein K13. As a pro-drug, ART is activated primarily by heme, which is mainly derived from hemoglobin digestion in the food vacuole. Activated ARTs can react promiscuously with a wide range of cellular targets, disrupting cellular protein homeostasis. Consistent with this mode of action for ARTs, the molecular mechanisms of K13-mediated ART resistance involve reduced hemoglobin uptake/digestion and increased cellular stress response. Mutations in other genes such as AP-2μ (adaptor protein-2 μ subunit), UBP-1 (ubiquitin-binding protein-1), and Falcipain 2a that interfere with hemoglobin uptake and digestion also increase resistance to ARTs. ART resistance has facilitated the development of resistance to the partner drugs, resulting in rapidly declining ACT efficacies. The molecular markers for resistance to the partner drugs are mostly associated with point mutations in the two food vacuole membrane transporters PfCRT and PfMDR1, and amplification of pfmdr1 and the two aspartic protease genes plasmepsin 2 and 3. It has been observed that mutations in these genes can have opposing effects on sensitivities to different partner drugs, which serve as the principle for designing triple ACTs and drug rotation. Although clinical ACT resistance is restricted to Southeast Asia, surveillance for drug resistance using in vivo clinical efficacy, in vitro assays, and molecular approaches is required to prevent or slow down the spread of resistant parasites.

Keywords: Artemisinin; Drug resistance; Hemoglobin digestion; K13; Molecular surveillance; Piperaquine; Plasmodium falciparum; Stress response; pfcrt; pfmdr1.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antimalarials* / pharmacology
  • Antimalarials* / therapeutic use
  • Drug Resistance / genetics
  • Humans
  • Malaria, Falciparum* / drug therapy
  • Plasmodium falciparum / genetics
  • Protozoan Proteins / genetics

Substances

  • Antimalarials
  • Protozoan Proteins